Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1198 • ACR Convergence 2020
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁶, Ritu Gill⁷, Hiroto Hatabu⁸, Mizuki Nishino⁸, Cynthia Crowson⁹, John Davis¹, Michael Weinblatt⁴, Nancy Shadick¹⁰, Tracy J. Doyle¹¹ and Jeffrey Sparks¹⁰, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Division of General Internal Medicine; Brigham and Women’s Hospital, Topsfield, MA, ⁷Department of Radiology; Harvard Medical School, Beth Israel Deaconess Medical Center, Topsfield, MA, ⁸Department of Radiology; Brigham and Women’s Hospital, Boston, ⁹Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Despite the known excess mortality of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its association with certain lifestyle factors such as obesity and future prediction…
Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
John Tesser¹, Grace Wright², Vibeke Strand³, Jeffrey Kaine⁴, Karina Maslova⁵, Gregory St John⁶, Kerri Ford⁵, Amy Praestgaard⁵ and Ernest Choy⁷, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Association of Women in Rheumatology, New York, NY, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Independent Rheumatology Consultant, Sapphire, NC, ⁵Sanofi, Cambridge, MA, ⁶Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…
Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Andrea Rubbert Roth¹, Daniel Furst*², Stefano Fiore³, Amy Praestgaard⁴, Vivian Bykerk⁵, Clifton Bingham III⁶ and Christina Charles-Schoeman⁷, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
Abstract Number: 1414 • ACR Convergence 2020
Highly Polyfunctional Metabolically Altered Pathogenic T Cells Accumulate in the Synovial Tissue of RA Patients and Arthralgia Subject but Not Healthy Control Synovial Tissue
Achilleas Floudas¹, Barry Moran², Nuno Neto³, Michael Monaghan⁴, Vinod Krishna⁵, Sunil Nagpal⁶, Phil Gallagher⁷, Conor Hurson⁸, Douglas Veale⁹ and Ursula Fearon¹⁰, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ²Trinity Biomedical Sciences Institute, Dublin, Ireland, ³Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, ⁴Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, ⁵Janssen R&D, Spring House, PA, ⁶Janssen Research & Development, Collegeville, PA, ⁷St Vincents University Hospital, UCD, Dublin, Ireland, ⁸St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ¹⁰Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…
Abstract Number: 1530 • ACR Convergence 2020
Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction
Helge Scholz¹, Iris Aykara¹, Klaus Frommer², Stefan Rehart³, Ulf Müller-Ladner⁴ and Elena Neumann¹, ¹Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany, ²Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, ³Department of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital, Frankfurt, Frankfurt, Germany, ⁴Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany
Background/Purpose: Activin A and follistatin belong to an anti-inflammatory auto-regulatory cycle. Patients with rheumatoid arthritis (RA) have increased activin A levels in the synovial fluid…
Abstract Number: 1593 • ACR Convergence 2020
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative
Tara Skorupa¹ and Robert Shmerling², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. HCQ may rarely cause retinopathy.…
Abstract Number: 1717 • ACR Convergence 2020
Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort
Joanna Kedra¹, David Hajage¹, Alexandre Lafourcade¹, Bernard Combe², Maxime Dougados³ and Bruno Fautrel⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²University of Montpellier, Montpellier, France, ³Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁴Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Long-term observational studies on the prediction of favorable outcome (FO) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely evaluated…
Abstract Number: 1733 • ACR Convergence 2020
Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Rosa Morlà¹, Tengfei Li², Jose Inciarte-Mundo³, Isabel Castrejon Fernandez⁴, Jose Gómez-Puerta⁵, Raimon Sanmartí⁵ and Theodore Pincus⁶, ¹Hospital Universitari Clínic de Barcelona, Barcelona, Spain, ²Georgetown University, Washigton, ³Hospital Universitari Clínic de Barcelona, Barcelona, ⁴Hospital General Universitario Gregorio Marañón, Chicago, IL, ⁵Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher comorbid depression and/or fibromyalgia (FM) than the general population. A multidimensional health-assessment questionnaire (MDHAQ) includes two queries…
Abstract Number: 1751 • ACR Convergence 2020
Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
Elston He¹, Eli Cornblath², Pratyusha Yalamanchi³, Alexis Ogdie², Joshua Baker² and Michael George², ¹Synovium, Inc., Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Michigan Medicine, Ann Arbor, MI
Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
Abstract Number: 1774 • ACR Convergence 2020
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Nevena Rebic¹, Ria Garg², Sarah Munro², Glen Hazlewood³, Neda Amiri², Nick Bansback², Stephanie Ensworth², Corisande Baldwin⁴, Laurie Proulx⁵ and Mary De Vera¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Calgary, AB, Canada, ⁵Canadian Arthritis Patient Alliance, Ottawa, Canada
Background/Purpose: Despite guidelines for managing rheumatoid arthritis (RA) in pregnancy, high rates of discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) considered safe for women with RA…
Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…
Abstract Number: 2010 • ACR Convergence 2020
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial
Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joseph Sexton¹, Inge C. Olsen², Åse Lexberg³, Tor Magne Madland⁴, Hallvard Fremstad⁵, Christian Høili⁶, Gunnstein Bakland⁷, Cristina Spada⁸, Hilde Haukeland⁹, Inger Myrnes Hansen¹⁰, Ellen Moholt¹, Till Uhlig¹, Daniel H. Solomon¹¹, Désirée van der Heijde¹², Tore K. Kvien¹ and Espen A. Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Vestre Viken HF, Drammen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Ålesund Hospital, Ålesund, Norway, ⁶Hospital Øsftfold HF, Moss, Norway, ⁷University Hospital of North Norway, Tromsø, Norway, ⁸Revmatismesykehuset, Lillehammeer, Norway, ⁹Martina Hansens Hospital, Bærum, Norway, ¹⁰Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Remission is the preferred treatment target in rheumatoid arthritis (RA), and many patients require biologic disease-modifying antirheumatic drugs (DMARDs) to reach this state. It…
Abstract Number: 0042 • ACR Convergence 2020
Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity
Rahaf Baker¹, Jonathan Graf², Laura Trupin², Sarah Goglin³, Patricia Katz⁴, Jennifer Barton⁵, Jean Liew⁶ and Katherine Wysham⁷, ¹Highland Hospital Internal Medicine, Oakland, CA, ²UCSF, San Francisco, CA, ³University of California San Francisco, Burlingame, CA, ⁴University of California, San Francisco, Novato, CA, ⁵VAPORHCS/OHSU, Portland, OR, ⁶University of Washington, Seattle, WA, ⁷VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Although management of RA has improved greatly over the past two decades with the advent of novel therapeutics, racial/ethnic and socioeconomic disparities persist. Traditional…
Abstract Number: 0131 • ACR Convergence 2020
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Anahy María Brandy García¹, Melania Martinez-Morillo², Agueda Prior³, Rosa Serrano¹, Lourdes Mateo⁴, Monica Guma⁵ and Laia Gifre², ¹Hospital Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, Spain, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…
Abstract Number: 0155 • ACR Convergence 2020
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
William Nowell¹, Elaine Karis², Kelly Gavigan³, Laura Stradford³, Scott Stryker², Huifeng Yun⁴, Shilpa Venkatachalam⁵, Gregory Kricorian², Lang Chen⁴, Hong Zhao⁶, Fenglong Xie⁶ and Jeffrey R Curtis⁴, ¹Global Healthy Living Foundation, New York City, NY, ²Amgen Inc., Thousand Oaks, CA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].